What’s The Outlook For The BioCryst Pharmaceuticals, Inc. (BCRX)?

What’s The Outlook For The BioCryst Pharmaceuticals, Inc. (BCRX)?

What’s The Outlook For The BioCryst Pharmaceuticals, Inc. (BCRX)?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is expected to announce second quarter financial results after market close (confirmed) on August 10, 2017. The company added about -10.8% percent in value since last earnings when it was at $6.47. Based on the most relevant historical data, there is a 66 percent probability for share price to go down following the next earnings report. Looking further into earnings reaction history, the stock had moved down 20 times out of last 30 quarters. It has topped earnings-per-share estimates 66% of the time in its last 12 earnings reports. It missed earnings on 2 occasions, and it has met expectations 2 time.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings Reaction History

Overall, the average earnings surprise was 30.65 percent over the past four quarters. Back on Mar 10, it posted earnings per share at $-0.19 which missed the consensus $-0.19 projection (Negative surprise of 0.00%). Revenue came in at $9.44M versus consensus estimate of $5.26M. The stock dropped -10.51% percent the day following the earnings was released, and on 7th day price change was -7.57% percent.

On February 27, 2017, it posted earnings per share at $-0.06 versus the consensus estimate of $-0.23 (Positive surprise of 73.90%). Revenue of $8.98M was above the $4.13M analysts had expected. The stock gained 0.36% the day following the earnings was released, and on 7th day price change was 39.89%.

On November 07, 2016, it posted earnings per share at $-0.16, topped the consensus estimate of $-0.24 (Positive surprise of 33.30%). Revenue for the quarter was $7.76M while analysts had expected revenues to come in at $5.76M. The stock gained 14.83% the day following the earnings was released, and on 7th day price change was 24.07%.

On August 04, 2016, it posted earnings per share at $-0.22 compared with the consensus estimate of $-0.26 (Positive surprise of 15.40%). That came on revenues of $4.79M for the quarter. Analysts had expected $3.92M in revenue.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings Expectations

In front of Q3 earnings release, Wall Street is expecting earnings per share of $-0.19. The analysts’ current consensus range is $-0.22-$-0.15 for EPS. The market consensus range for revenue is $4M-$9.6M, with an average of $5.79M.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) last closed at $5.56, sending the company’s market cap around $463.98M. The consensus 12-month price target from brokerage firms covering the stock is $8.63 . The share price has declined -39.89% from its best level in 52 weeks and advanced -12.16% this year. It recently traded in a range of $5.54-$5.82 at a volume of 805,058 shares. The stock ended last trading session with the price nearly -9.15% lower for the last 5 trading days, rebounding 98.57% from its 52-week low.